Hi Sam, I also enjoy reading George's posts so I like to hear...

Hi Sam,
I also enjoy reading George's posts so I like to hear his thoughts.
In this case, possibly like yourself, I don't see anything significant happening before the tox study or the ph2b outcome.
There may be something that comes about with Limb Girdle, maybe some sort of collaboration or other involvement, but regardless of what was said I think the tox study is extremely relevant to the market scale if the tox study is successful, and obviously the 2b trial itself is pivotal if successful.
I think everyone involved in the game knows what we are potentially looking at, and we are all aware the journey has been long, let's not get involved in any premature decision-making.
The tox study may not stop a form of diminished commercialisation but you only have to consider what an unsuccessful tox study could do to perceptions that would then diminish are negotiating strength.
Because negative results in the tox study probably would mean PML, and that would be a smear on the ATL brand.
However, I expect a positive outcome based on the successful MS 2a trial of 200mg shots and the cumulative weekly totals of 400mg and 600mg, with no PML. I think the primates are in a safe zone.
So for me, waiting for a successful Tox study is definitely worth the wait, and adds great value in the absence of any safety concerns, at all. That's what parents, the boys, and the developers all want as the best outcome, with no safety concerns.
Then you have the trial outcome, and again what the boys the parents, and the developers all want is a positive result, efficacy.
You put zero safety concerns with a product that is effective and what have you got,? ... a highly desirable commercial product.
And I can't imagine a world where our Board is not aware of these things and would consider doing any deal beforehand unless it was a deal that is bold upfront and extrapolates commercial royalties that would be maximized in the eyes of the owners.
A sale prior to results would be a negligent act in my opinion, unless of course as suggested it was extraordinary and broke Australian or US records,lol.
The only time a sale before results was viable would be if the trial was unsuccessful, but no one would know that for that to happen, so it's mute.
For me, the strongest negotiation point is between May and August 2024.
There would be work going on before then, but commitments and announcements in that time period.
It will also allow time for the share price to grow substantially which would satisfy some of the discussions AKKI has put forward about positions of strength based on capitalisation and equity.
And if Tox and 2b are successful, the share price should have risen substantially.
I also don't rule out going it alone, primarily. It would be difficult and would require some good strategic moves potentially licensing out something other than DMD, for funding, and I'm not suggesting it's likely, but I also don't think it's impossible.
Another small aspect that might be unlikely but not impossible, for me, is an involvement from ISIS, although not discussed much they have been on the journey the whole way and have silently in the background been there for mentorship and advice and resource, and it could be in their best interest to help our best interests.
Anyway, too much midnight speculation on my behalf there, but regarding action from us I would be disappointed if we didn't utilise the euphoric effects of successful tox and ph2b studies in negotiating from positions of absolute strength.